281 related articles for article (PubMed ID: 17943690)
1. Combined therapy of rhein and benazepril on the treatment of diabetic nephropathy in db/db mice.
Jia ZH; Liu ZH; Zheng JM; Zeng CH; Li LS
Exp Clin Endocrinol Diabetes; 2007 Oct; 115(9):571-6. PubMed ID: 17943690
[TBL] [Abstract][Full Text] [Related]
2. Effects of benazepril on renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in diabetic rats.
Sun SZ; Wang Y; Li Q; Tian YJ; Liu MH; Yu YH
Chin Med J (Engl); 2006 May; 119(10):814-21. PubMed ID: 16732983
[TBL] [Abstract][Full Text] [Related]
3. Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice.
Liao J; Kobayashi M; Kanamuru Y; Nakamura S; Makita Y; Funabiki K; Horikoshi S; Tomino Y
J Nephrol; 2003; 16(6):841-9. PubMed ID: 14736011
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy.
Katavetin P; Eiam-Ong S; Suwanwalaikorn S
J Med Assoc Thai; 2006 Feb; 89(2):170-7. PubMed ID: 16579002
[TBL] [Abstract][Full Text] [Related]
5. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
Moriyama T; Oka K; Ueda H; Imai E
Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
[TBL] [Abstract][Full Text] [Related]
6. Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis.
Mathew R; Futterweit S; Valderrama E; Tarectecan AA; Bylander JE; Bond JS; Trachtman H
Am J Physiol Renal Physiol; 2005 Oct; 289(4):F911-21. PubMed ID: 15942051
[TBL] [Abstract][Full Text] [Related]
7. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy.
Salako BL; Finomo FO; Kadiri S; Arije A; Olatosin AO
Afr J Med Med Sci; 2002 Mar; 31(1):53-7. PubMed ID: 12518931
[TBL] [Abstract][Full Text] [Related]
8. Effect of enalapril and losartan on the events that precede diabetic nephropathy in rats.
Volpini RA; da Silva CG; Costa RS; Coimbra TM
Diabetes Metab Res Rev; 2003; 19(1):43-51. PubMed ID: 12592643
[TBL] [Abstract][Full Text] [Related]
9. Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis.
Ji Z; Huang C; Liang C; Chen B; Chen S; Sun W
Cell Mol Immunol; 2005 Apr; 2(2):150-4. PubMed ID: 16191423
[TBL] [Abstract][Full Text] [Related]
10. 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice.
Ichinose K; Maeshima Y; Yamamoto Y; Kinomura M; Hirokoshi K; Kitayama H; Takazawa Y; Sugiyama H; Yamasaki Y; Agata N; Makino H
Diabetes; 2006 May; 55(5):1232-42. PubMed ID: 16644677
[TBL] [Abstract][Full Text] [Related]
11. Increased urinary type IV collagen marks the development of glomerular pathology in diabetic d/db mice.
Cohen MP; Lautenslager GT; Shearman CW
Metabolism; 2001 Dec; 50(12):1435-40. PubMed ID: 11735089
[TBL] [Abstract][Full Text] [Related]
12. SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice.
Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
Am J Physiol Renal Physiol; 2006 Apr; 290(4):F813-20. PubMed ID: 16278277
[TBL] [Abstract][Full Text] [Related]
13. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
[TBL] [Abstract][Full Text] [Related]
14. [The experimental study of captopril and valsartan on the preventing and treatment of diabetic retinopathy in diabetic mice].
Xie XW; Zhao P
Zhonghua Yan Ke Za Zhi; 2004 Nov; 40(11):770-3. PubMed ID: 15634486
[TBL] [Abstract][Full Text] [Related]
15. Enhanced effect of combined treatment with SMP-534 (antifibrotic agent) and losartan in diabetic nephropathy.
Sugaru E; Nakagawa T; Ono-Kishino M; Nagamine J; Tokunaga T; Kitoh M; Hume WE; Nagata R; Taiji M
Am J Nephrol; 2006; 26(1):50-8. PubMed ID: 16508247
[TBL] [Abstract][Full Text] [Related]
16. Suppression of transforming growth factor-beta1 gene expression by Danggui buxue tang, a traditional Chinese herbal preparation, in retarding the progress of renal damage in streptozotocin-induced diabetic rats.
Zhang YW; Xie D; Xia B; Zhen RT; Liu IM; Cheng JT
Horm Metab Res; 2006 Feb; 38(2):82-8. PubMed ID: 16523407
[TBL] [Abstract][Full Text] [Related]
17. Tranilast prevents the progression of experimental diabetic nephropathy through suppression of enhanced extracellular matrix gene expression.
Akahori H; Ota T; Torita M; Ando H; Kaneko S; Takamura T
J Pharmacol Exp Ther; 2005 Aug; 314(2):514-21. PubMed ID: 15857946
[TBL] [Abstract][Full Text] [Related]
18. Effect of rhein on glucose transporter-1 expression and its function in glomerular mesangial cells.
Zhang J; Liu Z; Chen Z; Li Y; Li L
Chin Med J (Engl); 1999 Dec; 112(12):1077-9. PubMed ID: 11721442
[TBL] [Abstract][Full Text] [Related]
19. [Expression of type I transforming growth factor beta receptor in renal cortex in streptozotocin-induced diabetic rats and the regulation of benazepril].
Wu Y; Lin S
Zhonghua Nei Ke Za Zhi; 1999 Jan; 38(1):9-13. PubMed ID: 11798618
[TBL] [Abstract][Full Text] [Related]
20. Comparison between somatostatin analogues and ACE inhibitor in the NOD mouse model of diabetic kidney disease.
Segev Y; Eshet R; Rivkis I; Hayat C; Kachko L; Phillip M; Landau D
Nephrol Dial Transplant; 2004 Dec; 19(12):3021-8. PubMed ID: 15494355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
